Laurus Labs Q1FY25 Concall Highlights
Biosecure Act in the USA is a big benefit to Indian CDMO companies in the long run
Expect performance to pick up in H2
Gross Margin - 55% due to product mix, better pricing & process
Generic APIs had pricing pressure.
CAPEX - Animal health facility commercial validation going on. Agro facility will be commercialized end of FY25.R&D centre will be commissioned next month.
In the 2600cr Capex done already, 75% went towards CDMO facility.
CDMO – 70 active projects, 10 commercial projects. 5x increase in the scientist count in CDMO vertical in late-stage projects of big pharma which has high possibility of being successfully.
31 customer audits done in last year and half of them are CDMO. R2 facility is almost booked and R3 will come online in 24M, the fermentation facility with 200cr capex at R3 will come up by mid of 2026.
Oncology – New products validated at Vizag site and expecting regulatory approvals
FDF facility – 10 billion will be increased to 13billion in 18M
25% of facility is used for ARV currently
Krka JV – Expanded lines for oral solids in Vizag plant will go commercial in next 18M. Existing 2billion capacity given to them will be given additional 3billion capacity.
Subscribe To Our Free Newsletter |